Evidence map›Paper›PMID 21325655›Full record

ArticleClinical chemistry2011

Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR.

Jin Li, Pasi A Jänne, G Mike Makrigiorgos

Open access · bronzeAbstract read
In one paragraph

Article in Clinical chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. BEAMing sheds light on drug resistance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jin LiDepartment of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Pasi A Jänne
G Mike Makrigiorgos
Harvard University · US

Funding

Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE D · 2008 to 2012
$11.4M
SPORE in Lung CancerP20CA090578 · NCI · DANA-FARBER CANCER INSTITUTE · PI JOHNSON, BRUCE E. · 2003 to 2007
$5.1M
Drug Resistance in Lung CancerR01CA135257 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2008 to 2017
$3.5M
Technology for sensitive and reliable mutational profiling in pancreatic cancerR21CA138280 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2009 to 2011
$751k
NCI NIH HHS CA-090578NCI NIH HHS CA-135257NCI NIH HHS CA-138280NCI NIH HHS P20 CA090578NCI NIH HHS P50 CA090578NCI NIH HHS R01 CA135257NCI NIH HHS R21 CA138280
6 · The paper itself

Abstract

backgroundThe presence of the EGFR (epidermal growth factor receptor) T790M mutation in tumor tissue or body fluids from patients treated with EGFR tyrosine kinase inhibitors may indicate the onset of resistance to treatment. It is important to identify this mutation as early as possible so that treatment can be modified accordingly or potential side effects of further treatment can be avoided. This requirement calls for high detection sensitivity. Peptide nucleic acids (PNAs) are used as PCR clamps to inhibit amplification of wild-type DNA during PCR cycling, thereby enriching for rare mutations such as T790M. We describe a modification that improves the detection limit of PNA-clamp methods by at least 20-fold.

methodsWe enriched the target by exposing genomic DNA to an EGFR exon 20-specific biotinylated oligonucleotide, followed by binding to streptavidin beads. We then prepared serial dilutions of the isolated target DNA containing the T790M mutation by mixing with wild-type DNA and then performed PNA clamp-based, real-time TaqMan PCR. For comparison, we performed PNA clamp-based PCR directly on genomic DNA.

resultsWhereas the detection limit for PNA clamp-based PCR performed directly on genomic DNA is 1 mutant allele in 1000 wild-type alleles, conducting the assay with biotinylated oligonucleotide-enriched target DNA improved the detection limit to 1 mutant allele in 40,000 wild-type alleles. A possible explanation for the improvement in detection is that biotin-based target isolation efficiently eliminates wild-type DNA; therefore, fewer erroneous amplifications of wild-type DNA can occur early during the PCR.

conclusionsCombining target molecule isolation via a biotinylated probe with PNA-enriched TaqMan real-time PCR provides a major improvement for detecting the EGFR T790M resistance mutation.

Indexed as

BiotinCell Line, TumorDNADrug Resistance, NeoplasmErbB ReceptorsHumansLimit of DetectionLung NeoplasmsMaleMolecular ProbesMutationOligonucleotidesPeptide Nucleic AcidsPolymerase Chain ReactionBiotinDNAErbB ReceptorsMolecular ProbesOligonucleotidesPeptide Nucleic Acids

Identifiers

PMID21325655
PMCPMC3208327
OpenAlexW2103164029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.